Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of results from the dose-ranging Phase 2 STAR Study of tolperisone in patients with acute and painful muscle spasms of the lower back, in the Journal of Pain Research. “The published clinical data
November 23, 2020
· 2 min read